Cargando…

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

Detalles Bibliográficos
Autores principales: Hemming, Matthew L., Nathenson, Michael J., Lin, Jia-Ren, Mei, Shaolin, Du, Ziming, Malik, Karan, Marino-Enriquez, Adrian, Jagannathan, Jyothi P., Sorger, Peter K., Bertagnolli, Monica, Sicinska, Ewa, Demetri, George D., Santagata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055910/
https://www.ncbi.nlm.nih.gov/pubmed/32133433
http://dx.doi.org/10.1200/PO.19.00287
_version_ 1783503448047616000
author Hemming, Matthew L.
Nathenson, Michael J.
Lin, Jia-Ren
Mei, Shaolin
Du, Ziming
Malik, Karan
Marino-Enriquez, Adrian
Jagannathan, Jyothi P.
Sorger, Peter K.
Bertagnolli, Monica
Sicinska, Ewa
Demetri, George D.
Santagata, Sandro
author_facet Hemming, Matthew L.
Nathenson, Michael J.
Lin, Jia-Ren
Mei, Shaolin
Du, Ziming
Malik, Karan
Marino-Enriquez, Adrian
Jagannathan, Jyothi P.
Sorger, Peter K.
Bertagnolli, Monica
Sicinska, Ewa
Demetri, George D.
Santagata, Sandro
author_sort Hemming, Matthew L.
collection PubMed
description
format Online
Article
Text
id pubmed-7055910
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-70559102020-03-04 Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1 Hemming, Matthew L. Nathenson, Michael J. Lin, Jia-Ren Mei, Shaolin Du, Ziming Malik, Karan Marino-Enriquez, Adrian Jagannathan, Jyothi P. Sorger, Peter K. Bertagnolli, Monica Sicinska, Ewa Demetri, George D. Santagata, Sandro JCO Precis Oncol Case Reports American Society of Clinical Oncology 2020-02-14 /pmc/articles/PMC7055910/ /pubmed/32133433 http://dx.doi.org/10.1200/PO.19.00287 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Reports
Hemming, Matthew L.
Nathenson, Michael J.
Lin, Jia-Ren
Mei, Shaolin
Du, Ziming
Malik, Karan
Marino-Enriquez, Adrian
Jagannathan, Jyothi P.
Sorger, Peter K.
Bertagnolli, Monica
Sicinska, Ewa
Demetri, George D.
Santagata, Sandro
Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title_full Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title_fullStr Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title_full_unstemmed Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title_short Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
title_sort response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of ntrk1
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055910/
https://www.ncbi.nlm.nih.gov/pubmed/32133433
http://dx.doi.org/10.1200/PO.19.00287
work_keys_str_mv AT hemmingmatthewl responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT nathensonmichaelj responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT linjiaren responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT meishaolin responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT duziming responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT malikkaran responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT marinoenriquezadrian responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT jagannathanjyothip responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT sorgerpeterk responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT bertagnollimonica responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT sicinskaewa responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT demetrigeorged responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1
AT santagatasandro responseandmechanismsofresistancetolarotrectinibandselitrectinibinmetastaticundifferentiatedsarcomaharboringoncogenicfusionofntrk1